Photo from Pexels[/caption]
Fall Detection Technology
Dr. Howard[/caption]
Frederick Howard MD
Assistant Professor of Medicine
Section of Hematology / Oncology
University of Chicago
MedicalResearch.com: What is the background for this study?
Response: With the advent of AI language models like ChatGPT, these tools may be used to generate scientific literature or abstracts. Indeed, a survey conducted by Nature in 2023 found that nearly 30% of scientists were using AI tools to aid in the writing of scientific manuscripts. The use of AI in scientific literature can be difficult to identify, and previous studies suggest that human reviewers cannot distinguish between AI generated and human written scientific abstracts. Commercial tools designed to identify AI content may have a higher degree of accuracy, but the optimal approach to applying such tools to detect AI content within scientific literature is uncertain.
The nutrition label maker relies on food reference materials to produce accurate and up-to-date nutrition information. The reference materials are compilations of nutritional data detailing the nutrients in diverse foods and beverages.
Most food manufacturers prefer government-backed standard reference materials—such as those from the USDA (United States Department of Agriculture) and NIST (National Institute of Standards and Technology)—as they meet accuracy, trustworthiness, and reliability standards.
Manufacturers can also use scientifically developed food databases that are not affiliated with government agencies as their nutrition data source. Indeed, many players in the food production space rely on more than one database to process their products' nutrient data.
The more data a nutrition label maker has to comb through, the more extensive the nutrient information it can compile for every food ingredient. This is important for two main reasons:
Dr. Dräger[/caption]
Sarah Dräger, MD
Postdoc, BRCCH Researcher
Internal Medicine and ID specialist
Division of Internal Medicine
University Hospital Basel, Switzerland
Basel
MedicalResearch.com: What is the background for this study?
Response:In patients with severe infections and patients in the intensive care unit, therapeutic drug monitoring (TDM) may be used to optimize and personalize intravenous antibiotic treatment. In these patients, “conventional antibiotic dosing”, e.g. selection of the dose only considering the renal function and, if applicable, body weight, may lead to over- or underdosing due to an altered drug metabolism. This, in turn may be associated with worse clinical outcome or toxic side effects.
TDM is used to monitor antibiotic blood plasma concentrations and provides guidance to the clinicians to adjust the antibiotic dosing according to the TDM results. But the collection of blood is an invasive, time- and resource-consuming sample collection technique and leads to discomfort to the patients. Additionally, turnaround time may be long (3h to 8h), and analyses may be offered only twice or three time a week. This may be too late to guide antibiotic dosing timely in patients with a very dynamic drug metabolism. Therefore, alternatives are required to overcome the limitations of current TDM.
By using exhaled breath, we aim to develop an innovative therapeutic drug monitoring technique, which is non-invasive, easy to collect, not associated with discomfort to the patient, and which may allow to decrease the turnaround time, especially when combined with real-time analyses.
John W. Ayers, PhD MA
Vice Chief of Innovation | Assoc. ProfessorIn late 2022, X introduced Community Notes. This novel approach empowers volunteer, independent, anonymous, and ideologically diverse contributors to identify posts containing misinformation and to rectify misinformation by appending informative "notes" to suspect posts. The process is controlled by the public, instead of decision-makers at the company. Most importantly the system is open-sourced so it can be studied by external scientists.
Dr. Sathananthan[/caption]
Dr. Janarthanan Sathananthan M.D.
Chief Medical Officer for Interventional Cardiology Therapies
Boston Scientific
MedicalResearch.com: What is the background for this study?
Response: Despite significant improvements in the drug-eluting stents that are used to treat patients with coronary artery disease, 10% of the percutaneous coronary interventions (PCIs) in the U.S. today address in-stent restenosis (ISR), which is when a previously stented section of a coronary artery becomes obstructed or narrowed by plaque or scar tissue. These patients require additional intervention to avoid potential complications. In the multicenter, randomized AGENT IDE trial, we evaluated whether the AGENT™ Drug-Coated Balloon (DCB), a balloon catheter coated with anti-restenotic paclitaxel, is superior to an uncoated balloon in patients for treating ISR. The AGENT DCB is currently available in countries outside the U.S. Our goal is to bring this technology to market in the U.S. and finally provide physicians with an alternative to traditional ISR treatments, such as placing additional layers of stents or radiation, which may not provide ideal outcomes in some cases.
In October 2023, at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 meeting, we presented the primary endpoint data from our AGENT IDE randomized controlled trial evaluating clinical outcomes in patients with ISR undergoing treatment with the AGENT DCB or conventional balloon angioplasty. The positive results in this primary analysis cohort supported the device’s U.S. Food and Drug Administration (FDA) approval, which we announced on March 1, 2024. Just a few months later, data from the full cohort of 600 patients were published in the Journal of the American Medical Association (JAMA) and shared in a late-breaking presentation at Cardiovascular Research Technologies (CRT) 2024 meeting.
Dr. Das[/caption]
Jishnu Das, Ph.D.
Center for Systems Immunology
Departments of Immunology and Computational & Systems Biology,
Assistant Professor School of Medicine
University of Pittsburgh
MedicalResearch.com: What is the background for this study? How does this new AI model work? How is it different from other models?
Response: Modern multi-omic technologies generate an enormous amount of data across scales of organization, and with differing resolution. While recent machine learning methods have harnessed these to predict clinical/physiological outcomes, they are often black boxes that do not provide meaningful inference beyond prediction. Differences in data generation modalities, redundancy in the data, as well as large numbers of irrelevant features make inference of biological mechanisms from high-dimensional omic datasets challenging.
To address these challenges, we developed a machine learning technique called SLIDE (Significant Latent Factor Interaction Discovery and Exploration). We reasoned that features that are directly measured by current technologies are constrained by strengths and weaknesses of current platforms. So, while some observed features may be excellent correlates of outcomes of interest, inferring biological mechanisms from these multi-omic datasets requires us to delve beyond the observable into the hidden states, i.e., latent factors. These hidden states encapsulate the true drivers of underlying biological processes and capture a complex multi-scale interplay between entities measured by these datasets. Our method moves beyond simple biomarkers/correlates (“the what”) to hidden states that actually explain clinical/physiological outcomes (“the how” and “the why”).
Response: Atypical sensory processing is common in neurodevelopmental disorders, affecting approximately 60% of children with ADHD and up to 90% of children with autism. Sensory symptoms are associated with hyperactivity, restricted/repetitive behavior, irritability, behavioral problems, and emotional dysregulation. Sensory-related meltdowns and symptoms can be very disruptive to family-life, interfere with family participation in community events and are associated with increased caregiver stress.
Prior to this study there was little understanding of potential risk factors for atypical sensory processing.
The researchers used data from the National Children’s Study to determine the association between early-life screen time and sensory processing outcomes among toddlers.
Dr. Traverso[/caption]
Giovanni Traverso MD PhD
Karl Van Tassel (1925) Career Development Professor
Department of Mechanical Engineering
Koch Institute of Integrative Cancer Research
Division of Gastroenterology
Brigham and Women’s Hospital
Harvard Medical School, Boston, MA, USA
MedicalResearch.com: What is the background for this study?
Response: I think its always important to acknowledge that this is a big team effort. We have the teams from MIT, Celero Systems, West Virgnia University (WVU) and Brigham and Women’s Hospital (BWH) all working together on this. For this study, Celero prototyped the devices that we tested in pre-clinical (Swine) models and in a first-in-human study with the team at WVU.
Our lab focuses on the development of ingestible devices for drug delivery and sensing and these have informed the development of these efforts as you can see.
MedicalResearch.com: What types of vital signs are measurable in this fashion?
Response: Heart rate and respiratory rate.
Dr. Cheng[/caption]
HUANYU “LARRY” CHENG Ph.D.
Associate Professor and Dorothy Quiggle Career Development Professor in Engineering
James L. Henderson, Jr.
Memorial Associate Professor of Engineering Science and Mechanics
Penn State University
MedicalResearch.com: What is the background for this study?
Response: Although increasing efforts have been devoted to the development of non-invasive wearable electrochemical sweat sensors for monitoring physiological and metabolic information, most of them still suffer from poor stability and specificity over time and fluctuating pH and temperatures. laser-induced graphene is the low-cost platform for the early identification and continuous monitoring of different biomarkers for non-invasive disease diagnosis and treatment evaluation However, low sensitivity and limited surface area can limit the detection of ultra-low biomarker concentration in sweat or other fluids. As a result, a wide range of conductive nanomaterials has been incorporated into the porous structure of LIG to increase the available surface area, facilitate electron transfer, and enhance the electrocatalytic activity of the electrode but those nanomaterial modifications are hard to manufacture reproducibly, and they are not long-term stable.
Therefore, it is highly desirable to develop a highly sensitive, selective, low-cost, and long-term stable flexible sensing platform for continuous and accurate healthcare monitoring.
Dr. Hidde ten Berg[/caption]
Dr. Hidde ten Berg
Department Emergency Medicine and
[caption id="attachment_60847" align="alignleft" width="125"]
Dr. Steef Kurstjens[/caption]
Dr. Steef Kurstjens
Department of Clinical cChemistry and Haematology
Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands
MedicalResearch.com: What is the background for this study?
Response: At this moment we are still in the exploratory phase, and therefore, there is no widespread or routine usage of ChatGPT in Emergency Medicine. That said, there are instances where individual physicians have used ChatGPT for specific purposes. These may include facilitating bureaucratic tasks that can often be time-consuming, aiding in writing e-mails or texts, and serving as a brainstorming tool when dealing with complex medical cases and questions. Though not yet a standardized practice, these isolated examples demonstrate a growing interest for the potential application of this novel technology.
Dr. Ueda[/caption]
Dr. Daiju Ueda
Department of Diagnostic and Interventional Radiology
Graduate School of Medicine
Osaka Metropolitan University
Osaka, Japan
MedicalResearch.com: What is the background for this study?
Response: We were inspired by the potential of chest radiography as a biomarker for aging. Previous research had utilized chest radiographs for age estimation, but these studies often involved cohorts with diseases.
Dr. Dhingra[/caption]
Lovedeep Singh Dhingra, MBBS
Postdoctoral Research Associate
Cardiovascular Data Science (CarDS) Lab
Yale School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Wearable devices are shown to have multiple health-related features, including heart rate and activity monitoring, ECG tracing, and blood pressure monitoring.
In our analyses of the nationally-representative Health Information National Trends Survey (HINTS), we discovered that patients with and at risk of cardiovascular disease are less likely to use wearables. Older patients, patients with lower education, and patients with lower incomes are less likely to use wearables. Also, among adults with access to wearables, patients with cardiovascular disease use their devices less frequently as compared to the overall population.
Dr. Mak[/caption]
Raymond H. Mak, MD
Radiation Oncology Disease Center Leader for Thoracic Oncology
Director of Patient Safety and QualityDirector of Clinical Innovation
Associate Professor, Harvard Medical School
Cancer - Radiation Oncology, Radiation Oncology
Department of Radiation Oncology
Brigham and Women's Hospital
MedicalResearch.com: What is the background for this study? What is the algorithm detecting?
Response: Lung cancer, the most common cancer worldwide is highly lethal, but can be treated and cured in some cases with radiation therapy. Nearly half of lung cancer patients will eventually require some form of radiation therapy, but the planning for a course of radiation therapy currently entails manual, time-consuming, and resource-intensive work by highly trained physicians to segment (target) the cancerous tumors in the lungs and adjacent lymph nodes on three-dimensional images (CT scans). Prior studies have shown substantial variation in how expert clinicians delineate these targets, which can negatively impact outcomes and there is a projected shortage of skilled medical staff to perform these tasks worldwide as cancer rates increase.
To address this critical gap, our team developed deep learning algorithms that can automatically target lung cancer in the lungs and adjacent lymph nodes from CT scans that are used for radiation therapy planning, and can be deployed in seconds.
We trained these artificial intelligence (AI) algorithms using expert-segmented targets from over 700 cases and validated the performance in over 1300 patients in external datasets (including publicly available data from a national trial), benchmarked its performance against expert clinicians, and then further validated the clinical usefulness of the algorithm in human-AI collaboration experiments that measured accuracy, task speed, and end-user satisfaction.
Mr. Londoner[/caption]
Ken Londoner, MBA
Founder, Chief Executive Officer, Chairman, and Director
BioSig Technologies
MedicalResearch.com: Would you briefly describe the condition of Atrial fibrillation (AFib)?
Whom does AFib primarily affect and how common is it? What are the potential complication of AFib?
Response: Atrial Fibrillation, or Afib—the most common heart rhythm disturbance—affects over 33 million people across the globe. Afib is caused by faulty electrical signals in the upper chambers of the heart (the atria) that cause it to beat too fast or irregularly—often more than 400 beats per minute.* The condition can lead to serious health consequences, including stroke, blood clots, or sudden cardiac arrest. Stroke is among the most serious health concerns for Afib patients, with research suggesting a Afib carries a 5-fold increased risk of stroke— especially when Afib is left untreated.
With a lifetime risk of more than 20 percent*, Afib can affect anyone. However, the condition is most common in those 65 years and older. Individuals with underlying health complications, including heart disease, high blood pressure, thyroid problems, or excessive alcohol use are also at a greater risk of developing Afib.*
MedicalResearch.com: What is the background for the EVO procedure? Would you briefly describe what is meant by myopia and how common it is?
Response: EVO is a clinically-proven implantable lens that corrects common vision problems such as nearsightedness and nearsightedness with astigmatism. EVO can be the solution for people who want to get rid of their glasses or contact lenses. Myopia (or nearsightedness) is the most common ocular disorder worldwide and its incidence is increasing significantly. An estimated 30% of the world's population, or 2.6 billion people, have myopia and this number is projected to rise to 50% of the global population by the year 2050.
Ali M. Fazlollahi[/caption]
Ali M. Fazlollahi, MSc, McGill Medicine Class of 2025
Neurosurgical Simulation and Artificial Intelligence Learning Centre
Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital
Faculty of Medicine and Health Sciences
McGill University, Montreal, Canada
MedicalResearch.com: What is the background for this study?
Response: COVID-19 disrupted hands on surgical exposure of medical students and academic centres around the world had to quickly adapt to teaching technical skills remotely. At the same time, advances in artificial intelligence (AI) allowed researchers at the Neurosurgical Simulation and Artificial Intelligence Learning Centre to develop an intelligent tutoring system that evaluates performance and provides high-quality personalized feedback to students. Because this is the first AI system capable of providing surgical instructions in simulation, we sought to evaluate its effectiveness compared with learning from expert human instructors who provided coaching remotely.
Dr. Torkamani[/caption]
Ali Torkamani, Ph.D.
Director of Genomics and Genome Informatics
Scripps Research Translational Institute
Professor, Integrative Structural and Computational Biology
Scripps Research
La Jolla, CA 92037
MedicalResearch.com: What is the background for this study?
Response: Prior research has shown that people with higher polygenic risk for coronary artery disease achieve greater risk reduction with statin or other lipid lowering therapy. In general, adherence to standard guidelines for lipid lowering therapy is low - about 30% of people who should be on lipid lowering therapy are, with no correlation to their genetic risk. We set out to see whether communicating personalized risk, including polygenic risk, for coronary artery disease would drive the adoption of lipid lowering therapy.
Dr. Mahan[/caption]
Michael J. Mahan Ph.D
Professor
Dept of Molecular, Cellular, and Developmental Biology
University of California, Santa Barbara, CA 93106-9625
MedicalResearch.com: What is the background for this study?
Response: A critical need exists in resource-poor settings for low-cost, low-tech, yet highly reliable and scalable testing for SARS-CoV-2 virus that is robust against circulating variants.
Dr. Ware[/caption]
Dr Julia Ware
(née Fuchs)
Clinical Research Associate
Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories
and Medical Research Council Metabolic Diseases Unit, University of Cambridge
Addenbrooke’s Hospital, Cambridge
MedicalResearch.com: What is the background for this study?
Response: Management of type 1 diabetes is challenging in very young children, due to their high variability of insulin requirements and unpredictable eating and activity patterns. As a result, many young children do not meet the recommended glycemic targets, or only maintain recommended glycemic control with extensive caregiver input. This in turn leads to high management burden and reduced quality of life for the whole family.
While the increasing use of continuous glucose-monitoring devices and insulin-pump therapy has led to reductions in the incidence of severe hypoglycaemia and diabetic ketoacidosis, and has been accompanied by modest improvements in glycemic control, the burden of management has remained high. Hybrid closed-loop systems (also called an artificial pancreas), in which an algorithm automatically adjusts insulin delivery on the basis of real-time sensor glucose levels, may address ongoing challenges in this age group. However, to date hybrid closed-loop studies involving very young children have been small and of short duration and the efficacy and safety of longer term use of a closed-loop system, as compared with standard therapy, was unclear.
To address this knowledge gap, we compared 16-week use of the Cambridge closed-loop algorithm with sensor-augmented pump therapy in children aged 1 to 7 years with type 1 diabetes in a multi-national randomised crossover study.
Dr. Pollitt[/caption]
Krystal Pollitt, PhD, P.Eng.
Assistant Professor of Epidemiology (Environmental Health Sciences)
Assistant Professor in Chemical and Environmental Engineering
Affiliated Faculty, Yale Institute for Global Health
Yale School of Public Health
MedicalResearch.com: What is the background for this study?
Response: People infected with COVID-19 can release SARS-CoV-2 virus in aerosol and droplets when they exhale. This can be from coughing or sneezing but also when they speaker or just breathe. While the larger droplets can settle to the ground quickly (seconds to minutes), smaller aerosol can remain in the air in longer periods (minutes to hours). SARS-CoV-2 can be transmitted by inhaling aerosol or droplets containing infectious virus. The Fresh Air Clip enables detection of droplet and aerosol containing virus.